NSF Award
1448525
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project will be to improve the treatment and decrease the high costs associated with treating patients who suffer severe traumatic brain injuries. This project aims to develop an accurate, affordable (<$100 per use) and non-invasive device to monitor a patient?s intracranial pressure following traumatic brain injury. Increased intracranial pressure can result in serious condition or death, if left untreated. However, the only available method to monitor intracranial pressure is expensive (~$10,000 per patient) and requires neurosurgery. The lack of a method to accurately screen patients to determine who needs surgery results in misdiagnoses and incorrect treatment in about 46% of patients among an estimated 50,000 patients in the US alone, and hundreds of thousands more globally. Successful commercialization of product is expected to result in savings in the range $250 million ever year to the US healthcare system.<br/><br/>The proposed project will test the feasibility of developing a non-invasive intracranial pressure (ICP) monitoring method for use outside of the neuro ICU. To develop an accurate, affordable, and non-invasive ICP monitoring device, the team will first write and validate a software framework that analyzes Cerebral Blood Flow Velocity (CBFV) waveforms. CBFV waveforms are acquired non-invasively by using transcranial Doppler (TCD) ultrasonography. In order to use CBFVs to predict ICP, two novel signal-processing methods will be developed. First, the high noise levels typical to TCD-acquired waveforms will be reduced within a machine-learning framework. Second, we will use a method to track morphological features that predict ICP from the CBFV waveform. Both these approaches to signal processing to analyze CBFV waveforms are entirely novel. This approach is expected to allow for accurate (>92% of area under the diagnostic ROC) non-invasive real time monitoring at an affordable price point that is within current reimbursement limits for TCD procedures.
